Form 4: Foghorn CMO Granted 300,000 Stock Options

Foghorn Therapeutics' Chief Medical Officer, Alfonso Quintas-Cardama, was granted 300,000 stock options with a $5.71 exercise price.

Summary

• Alfonso Quintas-Cardama, Chief Medical Officer of Foghorn Therapeutics Inc. (FHTX), was granted 300,000 stock options.
• The options have an exercise price of $5.71 per share.
• The grant date for these options was January 30, 2026.
• The options will vest as to 25% of the underlying shares on January 30, 2027.
• Following the initial vesting, 6.25% of the underlying shares will vest on the first day of each calendar quarter.
• The options have an expiration date of January 29, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices and an effort to align management incentives with long-term company performance, without indicating any immediate operational or financial changes.

Positives

• The grant of 300,000 stock options to the Chief Medical Officer aligns management's interests with shareholder value creation.
• The long vesting schedule (over several years) encourages long-term commitment and performance from a key executive.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if exercised.

Future Outlook

The stock options have a vesting schedule extending to January 30, 2027, and quarterly thereafter, with an expiration date in 2036, indicating a long-term incentive structure for the Chief Medical Officer.

Industry Context

Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align executive interests with shareholder returns. StockSavvy.ai notes that such grants are common for key personnel in growth-oriented companies like Foghorn Therapeutics.

Comparison to Industry Standards

• StockSavvy.ai notes that a grant of 300,000 options to a Chief Medical Officer is a significant equity incentive, comparable to grants seen in similar-sized biotech firms for key executive roles.
• For example, a CMO at a clinical-stage biotech company with a market cap similar to FHTX (around $200-300M) might typically receive annual equity grants ranging from 100,000 to 500,000 options or RSUs, depending on company stage, performance, and individual contribution. This grant falls within the expected range for a key executive in this sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also potential for increased long-term value creation due to executive incentives.
• Employees: May signal stability and continued investment in key leadership.

Next Steps

• The stock options will begin vesting on January 30, 2027, with subsequent quarterly vesting.
• The Chief Medical Officer may choose to exercise these options at any point after they vest and before their expiration date of January 29, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for Foghorn Therapeutics. It's a standard practice to incentivize management and does not provide new insights into the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation.

Keywords

Foghorn Therapeutics, FHTX, stock options, executive compensation, Form 4, insider transaction, Alfonso Quintas-Cardama, Chief Medical Officer, equity grant